What are the specific indications for Zilucoplan?

Zilucoplan (Zilucoplan) is a new type of immunomodulatory drug mainly used to treat myasthenia gravis (MG; rare disease). It is a selective complement inhibitor that can reduce immune responses by inhibiting the activation of the complement system, thereby improving neuromuscular diseases caused by autoimmune responses. Myasthenia gravis is a disease caused by the immune system mistakenly attacking acetylcholine receptors (AChR) at the junctions between nerves and muscles. Patients usually present with symptoms such as muscle weakness and fatigue, especially in the eyes, throat and respiratory muscles.

The indications for zeleptide are specifically for those**AChR antibody-positive (AChR-Ab+)** adult patients with myasthenia gravis. The immune systems of these patients produce antibodies that attack and destroy acetylcholine receptors, causing a block in signaling between nerves and muscles, resulting in muscle weakness. Zeleptide can reduce this immune response and alleviate symptoms by inhibiting the complement system, especially the activation of the C5 complement component. C5 is a key component in the complement system. Activated C5 will trigger inflammatory responses and cell destruction. Zeleptide can effectively block this process and reduce muscle damage and decline.

The clinical use of zeleptide provides a new treatment option, especially for patients who have not responded well to other treatments. By controlling and reducing immune system attacks, zeleptide helps restore patients' muscle function, relieve symptoms and improve their quality of life. In some cases, zeleptide can significantly reduce acute exacerbations and improve long-term clinical remission rates, becoming a new hope for the treatment of myasthenia gravis.

Reference materials:https://www.drugs.com/zilucoplan.html